Back to Search
Start Over
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
- Source :
- Cell Reports
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. The number of COVID-19 cases and deaths in India has risen steeply, and a SARS-CoV-2 variant, B.1.617, is believed to be responsible for many of these cases. The spike protein of B.1.617 harbors two mutations in the receptor binding domain, which interacts with the angiotensin converting enzyme 2 (ACE2) receptor and constitutes the main target of neutralizing antibodies. Therefore, we analyze whether B.1.617 is more adept in entering cells and/or evades antibody responses. B.1.617 enters two of eight cell lines tested with roughly 50% increased efficiency and is equally inhibited by two entry inhibitors. In contrast, B.1.617 is resistant against bamlanivimab, an antibody used for COVID-19 treatment. B.1.617 evades antibodies induced by infection or vaccination, although less so than the B.1.351 variant. Collectively, our study reveals that antibody evasion of B.1.617 may contribute to the rapid spread of this variant.<br />Graphical abstract<br />Between March and May 2021, India reported a steep increase in COVID-19 cases that was linked to SARS-CoV-2 variants, including B.1.617. Hoffmann et al. show that the B.1.617 spike protein mediates robust entry into human cells and evades neutralization by antibodies produced upon infection and vaccination.
- Subjects :
- media_common.quotation_subject
Plasma protein binding
Antibodies, Monoclonal, Humanized
Antibodies, Viral
spike protein
Guanidines
Article
General Biochemistry, Genetics and Molecular Biology
Cell Line
03 medical and health sciences
0302 clinical medicine
Pandemic
Humans
antibodies
Protease Inhibitors
Receptor
cell entry
immune evasion
030304 developmental biology
media_common
0303 health sciences
biology
SARS-CoV-2
Convalescence
Vaccination
COVID-19
Esters
convalescence
mutations
Virology
COVID-19 Drug Treatment
3. Good health
Cell culture
Spike Glycoprotein, Coronavirus
Angiotensin-converting enzyme 2
biology.protein
Angiotensin-Converting Enzyme 2
Antibody
B.1.617
030217 neurology & neurosurgery
Protein Binding
Subjects
Details
- ISSN :
- 22111247
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Cell Reports
- Accession number :
- edsair.doi.dedup.....8a10cde9046f37654a4957880df6edf6
- Full Text :
- https://doi.org/10.1016/j.celrep.2021.109415